Skip to main content
. Author manuscript; available in PMC: 2019 Jan 6.
Published in final edited form as: Leukemia. 2018 Jul 5;33(1):75–87. doi: 10.1038/s41375-018-0188-8

Figure 7. Ibrutinib and Ruxolitinib are synergistic against G-CSFR-mutant human CD34+ cells.

Figure 7

Checkerboard assays showing percent viability of sorted retroviral-vector-transduced human CD34+ umbilical cord blood cells treated with the indicated doses of Ibrutinib (Ib) and/or Ruxolitinib (Rux).